Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: Filgrastim (G-CSF)
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Paclitaxel
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2004-07-01

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00002837

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-06-25

Last Posted Date: 2021-08-26

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Registration Number: NCT00004202

Locations: 🇺🇸
Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
Cancer Center of Albany Medical Center, Albany, New York, United States

and more 13 locations

Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 3

Completed

Conditions: Endometrial Cancer

First Posted Date: 2004-06-24

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 240

Registration Number: NCT00003691

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 70 locations

S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: amifostine trihydrate
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2004-06-24

Last Posted Date: 2012-06-14

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 57

Registration Number: NCT00003127

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States

and more 91 locations

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy
Procedure: surgery

First Posted Date: 2004-06-24

Last Posted Date: 2016-07-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 480

Registration Number: NCT00003317

Locations: 🇺🇸
Rapid City Regional Hospital, Rapid City, South Dakota, United States
🇺🇸
CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States
🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States

and more 13 locations

Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-06-22

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 324

Registration Number: NCT00002717

Locations: 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States

and more 49 locations

Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 1

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-06-18

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Registration Number: NCT00005048

Locations: 🇺🇸
Kaplan Cancer Center, New York, New York, United States
🇺🇸
Mount Sinai Medical Center, NY, New York, New York, United States

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Phase 2

Terminated

Conditions: Cervical Cancer
Endometrial Cancer
Fallopian Tube Cancer
Neurotoxicity
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Sarcoma

First Posted Date: 2004-06-16

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003624

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 5 locations

Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-06-16

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00003206

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States

and more 15 locations

Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-06-16

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00003242

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy